Shares of FibroGen (NASDAQ:FGEN) have earned an average rating of “Hold” from the eleven analysts that are covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, three have given a hold recommendation, four have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $66.67.
Several research firms recently commented on FGEN. ValuEngine upgraded shares of FibroGen from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. Mizuho restated a “hold” rating and set a $61.00 price target on shares of FibroGen in a report on Thursday, March 29th. Leerink Swann restated an “outperform” rating and set a $88.00 price target (up from $80.00) on shares of FibroGen in a report on Wednesday, February 28th. TheStreet upgraded shares of FibroGen from a “d” rating to a “c-” rating in a report on Tuesday, February 27th. Finally, Zacks Investment Research cut shares of FibroGen from a “hold” rating to a “sell” rating in a report on Monday, March 5th.
In other FibroGen news, Director Kalevi Kurkijarvi sold 4,000 shares of FibroGen stock in a transaction that occurred on Thursday, April 19th. The shares were sold at an average price of $47.69, for a total value of $190,760.00. Following the completion of the sale, the director now directly owns 24,000 shares in the company, valued at $1,144,560. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Thomas B. Neff sold 39,636 shares of FibroGen stock in a transaction that occurred on Wednesday, April 18th. The shares were sold at an average price of $48.56, for a total transaction of $1,924,724.16. Following the completion of the sale, the chief executive officer now owns 2,933,653 shares of the company’s stock, valued at $142,458,189.68. The disclosure for this sale can be found here. Insiders sold 460,035 shares of company stock valued at $24,505,952 over the last quarter. Corporate insiders own 13.60% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of FGEN. Bank of Montreal Can lifted its stake in FibroGen by 2,097.2% in the fourth quarter. Bank of Montreal Can now owns 3,186 shares of the biopharmaceutical company’s stock valued at $151,000 after acquiring an additional 3,041 shares during the last quarter. Fortaleza Asset Management Inc. raised its position in shares of FibroGen by 95.0% in the fourth quarter. Fortaleza Asset Management Inc. now owns 3,490 shares of the biopharmaceutical company’s stock valued at $165,000 after purchasing an additional 1,700 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of FibroGen by 41.9% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,883 shares of the biopharmaceutical company’s stock valued at $184,000 after purchasing an additional 1,147 shares during the period. Paloma Partners Management Co bought a new position in shares of FibroGen in the fourth quarter valued at approximately $255,000. Finally, BBR Partners LLC raised its position in shares of FibroGen by 18.0% in the fourth quarter. BBR Partners LLC now owns 6,556 shares of the biopharmaceutical company’s stock valued at $311,000 after purchasing an additional 1,000 shares during the period. Hedge funds and other institutional investors own 61.39% of the company’s stock.
FGEN stock opened at $46.40 on Friday. The company has a quick ratio of 9.70, a current ratio of 9.70 and a debt-to-equity ratio of 0.17. The company has a market cap of $3,852.28, a P/E ratio of -26.82 and a beta of 1.89. FibroGen has a 52 week low of $25.35 and a 52 week high of $63.00.
FibroGen (NASDAQ:FGEN) last posted its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.27) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.01. The business had revenue of $42.51 million during the quarter, compared to analysts’ expectations of $45.37 million. FibroGen had a negative net margin of 100.43% and a negative return on equity of 32.08%. analysts anticipate that FibroGen will post -1.35 earnings per share for the current year.
FibroGen Company Profile
FibroGen, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage.
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.